As of November 7, 2026, RenovoRx, Inc. is a publicly traded company (Nasdaq: RNXT); its largest reported holder is Orin Hirschman, with 9.8% on Schedule 13G/A of April 27, 2026. The largest insider holding is Ramtin Agah, the chief medical officer and a director, with 798,460 shares (1.7% of shares outstanding), per Form 4 of January 22, 2026 (Schedule 13G/A, April 27, 2026).
Is this your company?
About to sign with, pay or invest in RenovoRx, Inc.? See the free Snapshot first.
Free to see. No signup.
Is RenovoRx, Inc. a real, registered company?
- RenovoRx, Inc. files with the SEC under CIK 1574094 (its SEC filings).
- Its shares are listed under the ticker RNXT on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Mountain View, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under RenovoRx, Inc. in our court records and SEC 8-K records (as of 2026-11-07).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Orin Hirschman (filed 2026-04-27).
Who are RenovoRx, Inc.'s owners and officers?
RenovoRx, Inc.: incorporated in Delaware; business address in Mountain View, California; industry Surgical & Medical Instruments & Apparatus (Schedule 13G/A, 2026-11-06).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2026-04-09)
- : Executive Officer (Form D, 2026-04-09)
- : Executive Officer (Form D, 2026-04-09)
- : Executive Officer (Form D, 2026-04-09)
- : Director (Form D, 2026-04-09)
- : Director (Form D, 2026-04-09)
- : Director (Form D, 2026-04-09)
- : Director (Form D, 2026-04-09)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-06 | Boston Scientific Corp | 0% |
| Schedule 13G/A, 2026-04-27 | Orin Hirschman | 9.8% |
| Schedule 13G/A, 2026-01-30 | Orin Hirschman | 7.1% |
| Schedule 13G/A, 2025-11-13 | Awm Investment Company, Inc. | 2.4% |
| Schedule 13G/A, 2025-11-10 | Orin Hirschman | 7.1% |
| Schedule 13G/A, 2025-08-14 | Awm Investment Company, Inc. | 5.1% |
Questions about who owns RenovoRx, Inc.
Who owns RenovoRx, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of RenovoRx, Inc.: Orin Hirschman (9.8%, Schedule 13G/A, filed 2026-04-27).
When did Orin Hirschman buy into RenovoRx, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Orin Hirschman on this page is the Schedule 13G/A, filed 2025-11-10, reporting 7.1%; its latest, Schedule 13G/A filed 2026-04-27, reports 9.8%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on RenovoRx, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on RenovoRx, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on RenovoRx, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own RenovoRx, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief medical officer and a director: 798,460 shares (1.7% of shares outstanding) (Form 4, 2026-01-22).
- , the chief executive and a director: 364,340 shares (0.76% of shares outstanding), 50,983 held directly and 313,357 indirectly (Form 4, 2026-03-24).
- , the chief financial officer: 319,580 shares (0.66% of shares outstanding), 222,380 held directly and 97,200 indirectly (Form 4, 2026-09-15).
- , a director: 97,165 shares (0.20% of shares outstanding), held indirectly through an una s. ryan revocable trust (Form 4, 2026-06-24).
- , the vice president controller and pao: 12,595 shares (0.03% of shares outstanding) (Form 4, 2025-04-10).
Shares outstanding: 48,250,592 as of 2026-10-30, from the company's latest SEC cover page.
How much has RenovoRx, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2026-04-09 | $10M | $10M |
| Form D, 2024-04-22 | $11.14M | $15M |
| Form D, 2024-02-09 | $6.11M | $15M |
Latest IPO step: RenovoRx, Inc. withdrew its IPO registration (RW, 2026-10-16).
IPO filings: RW, 2026-10-16.
Keep reading
More on RenovoRx, Inc. and the records around it.
The people at RenovoRx, Inc.
- Laurence Marton is also named on 3 other Form D filings: Matternet, Inc. (Jun 2026)
RenovoRx, Inc. elsewhere on the record
- Company profile and every filing Apr 2026
- Form D filing Apr 2026
Companies that share a holder
- AWM Investment Company, Inc. also filed stake reports on 32 other companies: 908 Devices Inc. (Aug 2026), Brazil Potash Corp. (Aug 2026), EVERSPIN TECHNOLOGIES INC. (Aug 2026)
- Orin Hirschman also filed stake reports on 46 other companies: ASPEN AEROGELS, INC. (Oct 2026), Bionano Genomics, Inc. (Oct 2026), FENNEC PHARMACEUTICALS INC. (Oct 2026)
Related pages
Funding and filing history5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/renovorx-inc